Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061679 | 0.88 | PTGDR2 (0.61) | PTGDR2TDP1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL10232241 | 0.84 | ALDH1A1 (0.42) | POLBSMN1; SMN2MEN1KMT2APKM | |
| SCHEMBL15304413 | 0.79 | PTGDR2 (0.57) | PTGDR2TDP1POLBSMN1; SMN2GLA | |
| SCHEMBL14199206 | 0.77 | PTGDR2 (0.42) | PTGDR2TDP1POLBSMN1; SMN2GLA | |
| SCHEMBL17311050 | 0.76 | L3MBTL1 (0.54) | PTGDR2TDP1POLBSMN1; SMN2GLA | |
| SCHEMBL7828077 | 0.75 | MEN1 (0.45) | PTGDR2TDP1POLBSMN1; SMN2GLA | |
| SCHEMBL13698963 | 0.75 | TDP1 (0.38) | PTGDR2TDP1POLBSMN1; SMN2GLA | |
| SCHEMBL2061280 | 0.73 | MAPT (0.50) | PTGDR2POLBSMN1; SMN2KMT2APKM | |
| SCHEMBL7822874 | 0.72 | SLC9A1 (0.40) | PTGDR2POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10232248 | 0.71 | TDP1 (0.36) | TDP1POLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | PTGDR2 2577/4885TDP1 1885/4885POLB 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.